Biomed Partners

German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads

Swiss immuno-oncology start-up building presence in Maryland as lead HLA-derived program nears clinic

March fund-raisings equate to over 80% of 2021’s total venture capital raised and almost two-thirds of 2020’s total 

The Belgian company is branching out into alpha emitters and growing its geographical footprint

Plus AbbVie, Venatorx meet in Phase III and updates from MorphoSys, RefleXion, TG Therapeutics, Xeris and more

The $210 million series B round for Umoja Biopharma Inc. is evidence that the concept of in vivo immune cell reprogramming is gaining steam. The company will use the funding to advance into the clinic

Emerging Company Profile: Noema emerges from stealth with $59M to develop four clinical neurology programs in-licensed from Roche

Europe's best-performing biotechs took on more risk, raised the most money